The Associated Press reports that Takeda Pharmaceutical Co. will buy Switzerland''s Nycomed for $13.6 billion, giving Japan''s biggest drugmaker coveted access to emerging markets. The all-cash deal is the largest ever overseas takeover by a Japanese pharmaceutical company and underscores Takeda''s aggressive efforts to expand globally. The Osaka-based company is particularly keen to tap into rapidly growing regions such as Asia, Russia and Latin America. Nycomed''s products are sold in more than 100 countries. Europe accounts for about half its revenue, while emerging markets comprise 39 percent of sales. Its products include prescription drugs, such as the lung-disease drug Daxas, and drugs for common complaints such as gastric pains, allergies, asthma, chronic pain and osteoporosis.